
Are you up for taking Big Pharma's new 'skinny' jab?
16 March 2023
After a succession of Big Pharma failures for anti-obesity drugs, will Novo Nordisk's latest offering, that emerges from something of a dark cloud, be just another side effect ladened sticking plaster, or a boon for users and a cash cow for its manufacturer?